Livers donated after cardiac death safe for patients with liver cancer
the ONA take:
According to a recent study published in the American Journal of Transplantation, researchers from Mayo Clinic in Jacksonville, Florida, have found that patients with liver cancer have the same positive outcomes using organs donated by patients who died as a result of cardiac death.
For the study, researchers identified 397 patients with liver cancer who received a new liver. Of those, 340 were from a person died after brain death and 57 were donated after cardiac death. Results showed that cancer recurrence occurred in about 12% of patients in both groups.
Previous studies have suggest that livers donated after cardiac death result in worse outcomes in patients with liver cancer because the liver has suffered oxygen deprivation.
"Our program has one of the largest experiences in the world with liver transplants using donations after cardiac death," says the study's lead investigator, transplant surgeon Kristopher P. Croome, M.D. "We now know that these organs effectively offer new life for patients with liver cancer."
Patients with liver cancer have the same positive outcomes using organs donated by patients who died as a result of cardiac death.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|